The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Summary

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.

Conditions

• Oncology
• Breast Cancer
• Prostate Cancer
• Gynecologic Cancer
• Brain Tumor
• Brain Cancer
• Gynecologic Tumor
• Prostate Tumor
• Prostate Neoplasm
• Breast Tumor
• Radiation Toxicity
• Quality of Life
• Rectal Cancer
• Rectal Tumor
• Rectal Neoplasms
• Lung Cancer
• Lung Tumor
• Lung Neoplasm
• Esophageal Cancer
• Esophagus Cancer
• Esophageal Tumor
• Esophageal Neoplasm
• Esophagus Tumor
• Esophagus Neoplasm
• Pancreatic Cancer
• Pancreatic Tumor
• Pancreatic Neoplasms
• Head and Neck Cancer
• Head and Neck Neoplasms
• Head and Neck Tumor
• Tumor
• Neoplasms
• Bladder Cancer
• Bladder Neoplasm
• Liver Cancer
• Liver Neoplasms
• Liver Metastases
• Oligometastases

Interventions

RADIATION

Radiation therapy

Radiation therapy on the CE marked and FDA approved MR-Linac

Sponsors & Collaborators

• The Netherlands Cancer Institute

  collaborator OTHER

• Sunnybrook Health Sciences Centre

  collaborator OTHER

• M.D. Anderson Cancer Center

  collaborator OTHER

• The Christie NHS Foundation Trust

  collaborator OTHER

• Royal Marsden NHS Foundation Trust

  collaborator OTHER

• Medical College of Wisconsin

  collaborator OTHER

• Elekta Limited

  collaborator INDUSTRY

• Odense University Hospital

  collaborator OTHER

• Radboud University Medical Center

  collaborator OTHER

• Radiotherapiegroep

  collaborator OTHER

• Jules Bordet Institute

  collaborator OTHER

• University Hospital Tuebingen

  collaborator OTHER

• Radiotherapeutic Institute Friesland

  collaborator OTHER

• Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

  collaborator OTHER

• IRCCS Sacro Cuore Don Calabria di Negrar

  collaborator OTHER

• Austin Health

  collaborator OTHER_GOV

• Princess Margaret Hospital, Canada

  collaborator OTHER

• Università degli Studi di Brescia

  collaborator OTHER

• UMC Utrecht

  lead OTHER

Principal Investigators

• Helena M Verkooijen, Prof, Dr · Universitair Medical Centre Utrecht

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-02-01

Primary Completion

2030-02-01

Completion

2030-08-01

FDA Device

Yes

Countries

• United States
• Australia
• Belgium
• Canada
• Denmark
• Germany
• Italy
• Netherlands
• United Kingdom

Study Locations